Australia markets closed
  • ALL ORDS

    7,239.40
    +30.40 (+0.42%)
     
  • ASX 200

    7,014.20
    +31.50 (+0.45%)
     
  • AUD/USD

    0.7785
    +0.0055 (+0.71%)
     
  • OIL

    65.51
    +1.69 (+2.65%)
     
  • GOLD

    1,844.00
    +20.00 (+1.10%)
     
  • BTC-AUD

    61,919.81
    -3,450.91 (-5.28%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • AUD/EUR

    0.6405
    +0.0011 (+0.17%)
     
  • AUD/NZD

    1.0724
    -0.0028 (-0.26%)
     
  • NZX 50

    12,367.86
    -60.26 (-0.48%)
     
  • NASDAQ

    13,393.12
    +283.97 (+2.17%)
     
  • FTSE

    7,043.61
    +80.28 (+1.15%)
     
  • Dow Jones

    34,382.13
    +360.68 (+1.06%)
     
  • DAX

    15,416.64
    +216.96 (+1.43%)
     
  • Hang Seng

    28,027.57
    +308.90 (+1.11%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     

UPDATE 1-AstraZeneca's drug Tagrisso gets China nod for early lung cancer

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

(Adds details of treatment, background)

April 14 (Reuters) - AstraZeneca Plc said on Wednesday that China's health regulator expanded the use of Tagrisso, the British drugmaker's lung cancer treatment, in patients with a type of lung cancer when diagnosed at an early stage.

China's National Medical Products Administration (NMPA) approved Tagrisso as an adjuvant therapy for patients with early-stage lung cancer who have a mutation of the EGFR gene, AstraZeneca said.

The drug is now approved to treat early-stage lung cancer in more than a dozen countries, including, most recently, in the United States.

The drugmaker said the Chinese approval was based on positive results from a late-stage trial that showed Tagrisso cut the risk of disease recurrence or death by 83%.

The EGFR mutation is found in about a quarter of global lung cancer cases, and older generation of EGFR inhibitors include Roche's Tarceva and AstraZeneca's own Iressa. (Reporting by Vishwadha Chander in Bengaluru; Editing by Shailesh Kuber)